SEC Form 4 · accession 0001209191-17-025617
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Bristow
Officer — Pres. & Chief Executive Offic · Director
Period of report
Apr 4, 2017
Accepted (ET)
Apr 5, 2017 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 4, 2017 | S | 720 | $2.41 | D | 41,155 | D | |
| Common Stock | holding | — | — | — | 19,986 | I | By InvestocorTrust as sole Trustee | |
| Common Stock | holding | — | — | — | 25,459 | I | By NFS Custodian for Michael Bristow's IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan").
- F2Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) remaining 2,291 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 36,839 previously reported shares of common stock held directly.